ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tivunatamig

Also written as “PF-08634404” and “SSGJ-707”.

In Pfizer’s pipeline, PD-1xVEGF Bispecific Antibody. Its studies are mostly in Endometrial Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Stomach Neoplasms, led by 2 companies.

Drug pageAnti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 28, 202515 company-led studies, 15 open or runningLicense: 3SBio → Pfizer, May 2025Next primary completion: Oct 18, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer1010 open or runningphase 3since Oct 28, 2025Oct 28, 2025Oct 18, 2027phase 2 · NCT07227012
3SBioits history only55 open or runningphase 3since May 12, 2025Apr 8, 2024none ahead
  • Named in Pfizer’s own pipeline as tivunatamig PF-08634404, phase 3, as of Nov 3, 2026 (source).

Also a collaborator on its studies: Astellas Pharma.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 19, 2025Pfizer licensed it from 3SBioLicenseEverywhere outside China, with an option on China · announced · Pfizer (release)
  2. Oct 28, 2025First studies: 2 phase 3 studiesFirst studyNCT07222800, NCT07222566
  3. Nov 7, 20252 phase 2 studiesNCT07227415, NCT07227012
  4. Nov 7, 2025Phase 3 study in Small Cell Lung CarcinomaNCT07226999 · 550 planned · United States, Australia, China and more
  5. Jan 30, 2026Phase 3 study in Stomach NeoplasmsNCT07392892 · 840 planned · United States, Canada, China and more
  6. Feb 12, 2026Phase 2 study in Carcinoma, Transitional CellNCT07421700 · 132 planned · United States, Australia, China and more
  7. Mar 13, 20262 phase 2 studiesNCT07476287, NCT07489066
  8. May 5, 2026Phase 3 study in Endometrial NeoplasmsNCT07578649 · 600 planned · United States, Australia, China and more
  9. Jul 19, 2026Named tivunatamigINNProposed as its International Nonproprietary Name in WHO's List 135 · before, PF-08634404, SSGJ-707
  10. Sep 28, 2026Primary completion moved from 2031-07-22 to 2032-01-15Date moved laterphase 3 · +6 months · NCT07392892

Ahead

  1. Oct 18, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07227012
  2. Nov 2, 2027Primary completion: phase 2 study in Carcinoma, Renal CellNCT07227415
  3. Dec 28, 2027Primary completion: phase 2 study in Carcinoma, Transitional CellNCT07421700
  4. Mar 24, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07476287

TargetBeta

“PD-1xVEGF Bispecific Antibody”the company's pipeline, read by Claude · source
“A humanized immunoglobulin G4 (IgG4) bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and an…”NCIt, read by Claude
“A humanized immunoglobulin G4 (IgG4) bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human vascular endothelial growth factor (VEGF), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 23
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rulewigen-biomedicine-technology-shanghai-co-ltdphase 22
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rulecompass-therapeuticsphase 11

Studies

All 10 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07578649Endometrial Neoplasms · United States, Australia, China and more3RecruitingJun 1, 2029600
NCT07489066Carcinoma · United States, Australia, China and more2RecruitingJul 29, 2028120
NCT07476287Small Cell Lung Carcinoma · United States, Australia, Brazil and more2RecruitingMar 24, 202840
NCT07421700Carcinoma, Transitional Cell · United States, Australia, China and more2RecruitingDec 28, 2027132
NCT07392892Stomach Neoplasms · United States, Canada, China and more3RecruitingJul 22, 2031840
NCT07227415Carcinoma, Renal Cell · United States, Australia, China and more2RecruitingNov 2, 2027224
NCT07227012Carcinoma, Hepatocellular · United States, China, Japan and more2RecruitingOct 18, 2027138
NCT07226999Small Cell Lung Carcinoma · United States, Australia, China and more3RecruitingJun 14, 2030550
NCT07222800Intestinal Neoplasms · United States, Argentina, Australia and more3RecruitingFeb 23, 2030800
NCT07222566Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingFeb 27, 20291,410

How it is read

Names in the registry

  • “PF-08634404”, 10 entries
  • “SSGJ-707”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.